Generating AI analysis...
Revenue
$28.16B
-10.57% YoY
EPS (Basic)
$0.56
-60.00% YoY
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $28.16B | $31.49B | -10.57% |
Cost of Revenue | $6.68B | $8.12B | -17.77% |
Net Income | $3.16B | $7.87B | -59.90% |
EPS (Basic) | $0.56 | $1.40 | -60.00% |
EPS (Diluted) | $0.55 | $1.38 | -60.14% |
SG&A Expense | $7.21B | $6.91B | +4.31% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $216.19B | $220.17B | -1.81% |
Current Assets | $37.83B | $73.35B | -48.43% |
Total Liabilities | $128.22B | $120.88B | +6.07% |
Current Liabilities | $43.82B | $34.65B | +26.47% |
Stockholders' Equity | $87.7B | $99.02B | -11.43% |
Cash & Equivalents | $1.05B | $2.63B | -60.03% |
Long-Term Debt | $57.51B | $61.36B | -6.27% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $-691M | $4M | -17375.00% |
Investing Cash Flow | $6.33B | $-22.17B | +128.56% |
Financing Cash Flow | $-7.39B | $24.4B | -130.28% |
D&A | $3.47B | $3.06B | +13.30% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 11.2% | — | — |
ROE | 3.6% | — | — |
ROA | 1.5% | — | — |
Current Ratio | $0.863 | — | — |
Debt to Equity | $1.462 | — | — |
Other companies in Pharmaceuticals